- Insys bribed doctors to prescribe addictive opioids
- The firm will plead guilty to fraud
Insys Therapeutics (NASDAQ: INSY), Arizona-based pharmaceutical company, will plead guilty to fraud and has agreed to pay a $225 million fine, the U.S. Department of Justice said.
The DoJ said the firm bribed doctors to prescribe highly addictive opioids, which boosted sales of its Subsys drug.
“For years, Insys engaged in prolonged, illegal conduct that prioritized its profits over the health of the thousands of patients who relied on it,” U.S. Attorney Andrew Lelling in Massachusetts said.